Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other ...

Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan's ...

Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities “Our SITC presentations ...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

Funding will advance RegCell's first-in-class epigenetic regulatory T-cell reprogramming platform to first-in-human clinical trials in 2025 Strategic move to a U.S.-based entity will accelerate ...